59.35p -2.1 -3.4%
Last Trade - 27/05/20
| Market Cap | £450.1m |
| Enterprise Value | £-58.4m |
| Revenue | £567.7m |
| Position in Universe | 518th / 1828 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | TTM | 2020E | 2021E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|---|
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2020
|
31st Dec 2021
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia. Its products are Suboxone Film (buprenorphine and naloxone), Suboxone Tablet (buprenorphine and naloxone), and Subutex Tablet (buprenorphine). Its other products include RBP-6000 in ATRIGEL, RBP-7000 risperidone monthly depot, Arbaclofen placarbil for alcohol use disorder (AUD), Intranasal naloxone for treatment of opioid overdose and RBP-8000 cocaine esterase for cocaine intoxication. Its RBP-6000 buprenorphine monthly depot is developed for the treatment of opioid use disorder. Its RBP-7000 risperidone monthly depot is developed for treatment of schizophrenia.
| Last Annual | December 31st, 2019 |
| Last Interim | March 31st, 2020 |
| Incorporated | September 26, 2014 |
| Public Since | December 23, 2014 |
| No. of Shareholders: | n/a |
| No. of Employees: | 824 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | FTSE All Share , FTSE All Share Health Care , FTSE All Share Pharmaceuticals & Biotechnology , FTSEurofirst 300 Ex Eurozone, FTSE Smallcap , FTSE Smallcap Ex Its , , |
| Exchange | London Stock Exchange (Full) |
| Shares in Issue | 732,436,173 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 103-105 Bath Road, SLOUGH, SL1 3UH, United Kingdom |
| Web | http://indivior.com/ |
| Phone | +44 1753 217800 |
| Contact | () |
| Auditors | PricewaterhouseCoopers LLP |
As of 27/05/20, shares in Indivior are trading at 59.35p, giving the company a market capitalisation of £450.1m. This share price information is delayed by 15 minutes.
Shares in Indivior are currently trading at 59.35p and the price has moved by 25.36% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Indivior price has moved by 51.12% over the past year.
Of the analysts with advisory recommendations for Indivior, there are there are currently 1 "buy" , 3 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Indivior is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Indivior is scheduled to issue upcoming financial results on the following dates:
Indivior does not currently pay a dividend.
Indivior does not currently pay a dividend.
Indivior does not currently pay a dividend.
To buy shares in Indivior you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Indivior are currently trading at 59.35p, giving the company a market capitalisation of £450.1m.
Here are the trading details for Indivior:
Based on an overall assessment of its quality, value and momentum, Indivior is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Indivior are currently priced at 59.35p. At that level they are trading at 17.45% discount to the analyst consensus target price of 71.90.
Analysts covering Indivior currently have a consensus Earnings Per Share (EPS) forecast of -0.007 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Indivior. Over the past six months, the relative strength of its shares against the market has been 94.06%. At the current price of 59.35p, shares in Indivior are trading at 33.83% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Indivior PE ratio based on its reported earnings over the past 12 months is 5. The shares are currently trading at 59.35p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Indivior's management team is headed by:
Here are the top five shareholders of Indivior based on the size of their shareholding:
